Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) have been assigned a consensus rating of “Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $41.50.
PLRX has been the topic of several research reports. SVB Leerink assumed coverage on shares of Pliant Therapeutics in a research report on Wednesday, July 20th. They set an “outperform” rating and a $33.00 price target on the stock. HC Wainwright increased their target price on shares of Pliant Therapeutics from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Finally, Citigroup started coverage on Pliant Therapeutics in a research report on Thursday, September 1st. They set a “buy” rating and a $36.00 price objective for the company.
Pliant Therapeutics Stock Performance
PLRX stock opened at $21.30 on Wednesday. The business has a 50 day moving average of $22.35 and a 200-day moving average of $15.37. The firm has a market cap of $1.04 billion, a PE ratio of -7.03 and a beta of 1.26. The company has a quick ratio of 7.69, a current ratio of 7.69 and a debt-to-equity ratio of 0.07. Pliant Therapeutics has a 12-month low of $3.96 and a 12-month high of $26.25.
In other news, CEO Bernard Coulie sold 12,502 shares of the stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $22.54, for a total transaction of $281,795.08. Following the sale, the chief executive officer now directly owns 59,273 shares in the company, valued at approximately $1,336,013.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Pliant Therapeutics news, CEO Bernard Coulie sold 12,502 shares of the business’s stock in a transaction on Monday, September 12th. The stock was sold at an average price of $22.54, for a total transaction of $281,795.08. Following the completion of the transaction, the chief executive officer now owns 59,273 shares in the company, valued at approximately $1,336,013.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Eric Lefebvre sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 25th. The stock was sold at an average price of $25.05, for a total value of $125,250.00. Following the completion of the sale, the insider now owns 133,437 shares of the company’s stock, valued at $3,342,596.85. The disclosure for this sale can be found here. Insiders own 6.60% of the company’s stock.
Hedge Funds Weigh In On Pliant Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC bought a new stake in Pliant Therapeutics in the third quarter valued at $36,369,000. BlackRock Inc. raised its stake in Pliant Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 1,698,212 shares of the company’s stock worth $11,905,000 after buying an additional 10,338 shares during the period. Vanguard Group Inc. raised its holdings in Pliant Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 1,232,699 shares of the company’s stock worth $8,642,000 after buying an additional 14,289 shares during the period. First Light Asset Management LLC boosted its position in shares of Pliant Therapeutics by 87.0% during the second quarter. First Light Asset Management LLC now owns 769,370 shares of the company’s stock worth $6,163,000 after buying an additional 358,042 shares during the period. Finally, Granahan Investment Management LLC grew its position in Pliant Therapeutics by 79.1% in the first quarter. Granahan Investment Management LLC now owns 489,334 shares of the company’s stock valued at $3,430,000 after purchasing an additional 216,149 shares in the last quarter. Institutional investors own 67.71% of the company’s stock.
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
- Get a free copy of the StockNews.com research report on Pliant Therapeutics (PLRX)
- The Cheesecake Factory Shows You Can Have It and Eat It Too
- Two EV Stocks That Could Rally Into Year-End
- 3 High Yields The Institutions Are Buying
- Can Activision Blizzard Rally Into Year End?
- 3 Old School Automakers Making Big EV Strides
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.